Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of imexon in patients with advanced malignancy.
Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R. Dragovich T, et al. Among authors: gordon m. J Clin Oncol. 2007 May 1;25(13):1779-84. doi: 10.1200/JCO.2006.08.9672. J Clin Oncol. 2007. PMID: 17470869 Clinical Trial.
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J. Margolin K, et al. Among authors: gordon ms. J Clin Oncol. 2001 Feb 1;19(3):851-6. doi: 10.1200/JCO.2001.19.3.851. J Clin Oncol. 2001. PMID: 11157039 Clinical Trial.
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Flaherty LE, et al. Among authors: gordon ms. J Clin Oncol. 2001 Jul 1;19(13):3194-202. doi: 10.1200/JCO.2001.19.13.3194. J Clin Oncol. 2001. PMID: 11432886 Clinical Trial.
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Clark JI, et al. J Clin Oncol. 2003 Aug 15;21(16):3133-40. doi: 10.1200/JCO.2003.02.014. Epub 2003 Jun 16. J Clin Oncol. 2003. PMID: 12810695 Clinical Trial.
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA. Sandler A, et al. Among authors: gordon m. Clin Cancer Res. 2004 May 15;10(10):3265-72. doi: 10.1158/1078-0432.CCR-03-0644. Clin Cancer Res. 2004. PMID: 15161679 Clinical Trial.
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. McDermott DF, et al. Among authors: gordon ms. J Clin Oncol. 2005 Jan 1;23(1):133-41. doi: 10.1200/JCO.2005.03.206. J Clin Oncol. 2005. PMID: 15625368 Clinical Trial.
4,260 results